Mohamed S Dabour

Mr. Mohamed S Dabour

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2024 in JACC: Cardiooncology
Verified
Journal Article
Open access
MDMohamed S Dabour
Mohamed S Dabour
MGMina Y. George
Mina Y. George
MDMary R. Daniel
Mary R. Daniel
ABAnne H. Blaes
Anne H. Blaes
BZBeshay Zordoky
Beshay Zordoky
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, originally approved for type 2 diabetes mellitus, have demonstrated efficacy in reducing cardiovascular events, particularly heart failure, in patients with and without diabetes. An intriguing research area involves exploring the potential application of SGLT2 inhibitors in cardio-oncology, aiming to mitigate the cardiovascular adverse events associated with anticancer treatments. These inhibitors present a unique dual nature, offering both cardioprotective effects and anticancer properties, conferring a double benefit for cardio-oncology patients. In this review, the authors first examine the established cardioprotective effects of SGLT2 inhibitors in heart failure and subsequently explore the existing body of evidence, including both preclinical and clinical studies, that supports the use of SGLT2 inhibitors in the context of cardio-oncology. The authors further discuss the mechanisms through which SGLT2 inhibitors protect against cardiovascular toxicity secondary to cancer treatment. Finally, they explore the potential anticancer effects of SGLT2 inhibitors along with their proposed mechanisms.

1 December 2020 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
IAIbrahim Y. Abdelgawad
Ibrahim Y. Abdelgawad
KSKarim T. Sadak
Karim T. Sadak
DLDiana W. Lone
Diana W. Lone
MDMohamed S Dabour
Mohamed S Dabour
LNLaura J. Niedernhofer
Laura J. Niedernhofer
BZBeshay Zordoky
Beshay Zordoky

30 May 2024 in Antioxidants
Verified
Journal Article
Open access
PDF file
MGMina Y. George
Mina Y. George
MDMohamed S Dabour
Mohamed S Dabour
EREman Rashad
Eman Rashad
BZBeshay Zordoky
Beshay Zordoky
Carfilzomib is an irreversible proteasome inhibitor used for multiple myeloma patients. However, carfilzomib treatment is associated with cardiovascular complications. Empagliflozin, an Sodium Glucose Co-transporter 2 inhibitor (SGLT-2) inhibitor, is an oral antidiabetic drug with proven antioxidant and anti-inflammatory properties. The aim of the present study was to determine the cardioprotective effects of empagliflozin against carfilzomib-induced cardiotoxicity. C57BL/6 mice were randomly divided into four groups: control, empagliflozin, carfilzomib, and carfilzomib + empagliflozin. Empagliflozin prevented carfilzomib-induced cardiotoxicity by ameliorating histological alterations, CK-MB, and troponin-I. Moreover, it inhibited carfilzomib-induced oxidative damage and inflammation via its action on catalase activity, reduced glutathione levels and superoxide dismutase activity, and reduced nuclear factor-κB (p65) and cytokine levels. Mechanistically, empagliflozin abrogated endoplasmic reticulum stress induced by carfilzomib, as evidenced by the effect on the Glucose Regulated Protein-78 (GRP-78)/Activating Transcription Factor 6 (ATF6)/C/EBP homologous protein (CHOP) axis. Intriguingly, carfilzomib significantly induced autophagy, an effect that was further enhanced by empagliflozin, evidenced by increased LC3B and beclin-1 mRNA expression and reduced p62 expression. The effect of empagliflozin on apoptosis was confirmed by reduced expression of active caspase-3. Importantly, empagliflozin did not alter the cytotoxic effect of carfilzomib on human U266B1 multiple myeloma cells. our findings suggest that empagliflozin may provide a new therapeutic strategy to mitigate carfilzomib-induced cardiotoxicity in multiple myeloma patients.

14 August 2024 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
MDMohamed S Dabour
Mohamed S Dabour
IAIBRAHIM ABDELGAWAD
IBRAHIM ABDELGAWAD
BSBushra Sadaf
Bushra Sadaf
MDMARY RAPHEL DANIEL
MARY RAPHEL DANIEL
MGMarianne Grant
Marianne Grant
BZBeshay Zordoky
Beshay Zordoky
Irreversible cardiotoxicity limits the clinical application of doxorubicin (DOX). DOX-induced cardiotoxicity has been associated with induction of senescence and activation of the p38 MAPK pathway. Losmapimod (LOSM), an orally active p38 MAPK inhibitor, is an anti-inflammatory agent with cardioprotective effects. Nevertheless, the effect of LOSM against DOX-induced cardiotoxicity has not been reported. In this study, we determined the effects of LOSM on DOX-induced chronic cardiotoxicity in C57BL/6 N mice. Five-week-old C57BL/6 N mice were fed diet containing LOSM (estimated daily intake 12 mg/kg/day) or a control diet for four days. Thereafter, mice were randomized to receive six weekly intraperitoneal injections of either DOX (4 mg/kg) or saline. Three days after the last injection, cardiac function was assessed by trans-thoracic echocardiography. Activation of p38, JNK, and ERK1/2 MAPKs were assessed by immunoblotting in the heart and liver. Gene expressions of senescence, inflammatory, oxidative stress, and mitochondrial function markers were quantified using real-time PCR and serum inflammatory markers were assessed by Luminex. Our results demonstrated that LOSM attenuated p38 MAPK activation, ameliorated DOX-induced cardiac dysfunction, and abrogated DOX-induced expression of the senescence marker p21Cip1. Additionally, LOSM demonstrated anti-inflammatory effects, with reduced cardiac Il-1α and Il-6 gene expression in DOX-treated mice. Systemic inflammation, assessed by serum cytokine levels, showed decreased IL-6 and CXCL1 in both DOX-treated mice and mice on LOSM diet. LOSM significantly increased mitofusin2 gene expression, which may enhance mitochondrial fusion. These findings underscore the potential therapeutic efficacy of p38 MAPK inhibition, exemplified by LOSM, in ameliorating DOX-induced cardiotoxicity, senescence, and inflammation.


23 December 2025 in Cardiovascular Toxicology
Verified
Journal Article
Open access
PDF file
MDMARY RAPHEL DANIEL
MARY RAPHEL DANIEL
MGMarianne Grant
Marianne Grant
MDMohamed S Dabour
Mohamed S Dabour
MRMaria Razzoli
Maria Razzoli
FSFernando Souza-Neto
Fernando Souza-Neto
BZBeshay Zordoky
Beshay Zordoky
Doxorubicin (DOX)-induced cardiotoxicity is widely studied using C57BL/6 mice. However, potential substrain differences between C57BL/6J (6J) and C57BL/6N (6N) remain unexamined. Comparative studies are needed to improve preclinical reproducibility and translation. Fifteen-week-old male 6N and 6J mice received either DOX (8 mg/kg/week for 3 weeks) or saline. Body weight was monitored weekly, followed by echocardiography to assess cardiac function. Histopathology evaluated cardiac fibrosis, and bulk RNA sequencing identified differentially expressed genes, which were then validated by qPCR. DOX caused significant weight loss in 6N constituted by loss of both fat and fat-free mass, while 6J showed subtle changes. Echocardiography showed a significant ejection fraction decline only in 6J, while cardiac output, stroke volume, and heart weight were reduced in both. Gene expression analysis revealed significant upregulation of atrial natriuretic peptide and myosin heavy chains in both substrains, with B-type natriuretic peptide upregulation in 6N only. Transcriptomic analysis identified 518 upregulated and 203 downregulated genes in 6N, and 406 upregulated and 445 downregulated genes in 6J, with 113 and 115 commonly upregulated and downregulated genes, respectively. Gene set enrichment analysis revealed that DOX-treated 6N mice showed enrichment of TGF-beta signaling pathways, and suppression of IL-6–JAK–STAT3, epithelial-mesenchymal transition, and myogenesis pathways. In contrast, 6J exhibited enrichment of oxidative phosphorylation, p53 pathway, and reactive oxygen species pathways. Both substrains showed enrichment of apoptosis, unfolded protein response, TNFα signaling via NF-κB, and heme metabolism pathways and downregulation of Hedgehog Signaling and Interferon Gamma Response pathways. This study demonstrates substrain-dependent differences in DOX-induced cardiotoxicity, highlighting how genetic background affects cardiac function, gene expression, and pathway enrichment. Graphical Abstract Substrain-specific differences in doxorubicin-induced cardiotoxicity